Treatment related changes in antifibrinolytic activity in patients with polycythemia vera

References

• Cao M, Olsen RJ, Zu Y. Polycythemia vera: new clinicopathologic perspectives. Arch Pathol Lab Med 2006; 130: 1126–1132.
   PubMed Web of Science ®Google Scholar
• Levine RL, Gilliland DG. Myeloproliferative disorders. Blood 2008; 112: 2190–2198.
   PubMed Web of Science ®Google Scholar
• Cervantes F, Arellano-Rodrigo E, Alvarez-Lai-ran A. Blood cell activation in myeloproliferative neoplasms. Haematologica 2009; 94: 1484–1488.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Cipriani MC, Novarese L. Thrombosis and bleeding inpolycythemia vera and essential thrombocythemia: pathogenetic mechanisms and prevention. Best Pract Res Clin Haematol 2006; 19: 617–633.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myelopro-liferative disorders: pathogenetic facts and speculation. Leukemia 2008; 22: 2020–2028.
   PubMed Web of Science ®Google Scholar
• Finazzi G, Barbui T. Evidence and expertise in the management ofpolycythemia vera and essential thrombocythemia. Leukemia 2008; 22: 1494–1502.
   PubMed Web of Science ®Google Scholar
• Landolfi R, Di Gennaro L. Prevention of thrombosis in polycythemia vera and essential thrombocythemia. Haematologica 2008; 93: 331–335.
   PubMed Web of Science ®Google Scholar
• Caramazza D, Caracciolo C, Barone R et al. Correlation betweenleukocytosis and thrombosis in Philadelphia-negative chronic myeloproliferative neoplasms. Ann Hematol 2009; 88: 967–971.
   PubMed Web of Science ®Google Scholar
• Elliott MA, Tefferi A. Thrombosis and haemorrhage in poly-cythaemia vera and essential thrombocythaemia. Br J Haematol 2005; 128: 275–290.
   PubMed Web of Science ®Google Scholar
• Bucalossi A, Marotta G, Bigazzi C, Galieni P, Dispensa E. Reduction of antithrombin III, protein C, and protein S levels and activated protein C resistance in polycythemia vera and essential thrombocythemia patients with thrombosis. Am J Hematol 1996; 52: 14–20.
   PubMed Web of Science ®Google Scholar
• Rogé D, Kremplewska-Nalezyta E, Gadomska G, Drewniak W, Koczubik W. Plasminogenesis in blood of patients with chronic myeloproliferative syndromes. Pol Arch Med Wewn 2006; 115: 23–28.
   PubMedGoogle Scholar
• Evangelista V, Piccardoni P, White JG, de Gaetano G, Cerletti C. Cathepsin G-dependent platelet stimulation by activated poly-morphonuclear leukocytes and its inhibition by antiproteinases: role of P-selectin-mediated cell—cell adhesion. Blood 1993; 81: 2947–2957.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Evangelista V et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood 1999; 93: 2506–2514.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Evangelista V et al. Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera. Blood 2000; 96: 4261–4266.
   PubMed Web of Science ®Google Scholar
• Musolino C, Alonci A, Bellomo G et al. Myeloproliferative disease: markers of endothelial and platelet status in patients with essential thrombocythemia and polycythemia vera. Hematology 2000; 4: 397–402.
   PubMedGoogle Scholar
• Maeda NY, Lopes AA, da-Rocha TR, Chamone DA. Plasma anticoagulant system in patients with pulmonary hypertension. Braz J Med Biol Res 1990; 23: 251–254.
   PubMed Web of Science ®Google Scholar
• Wieczorek I, MacGregor IR, Prescott RJ, Ludlam CA. The fibrinolytic system and proteins C and S in treated polycythaemia rubra vera. Blood Coagul Fibrinolysis 1992; 3: 823–826.
   PubMed Web of Science ®Google Scholar
• Braaten JV, Handt S, Jerome WG, Kirkpatrick J, Lewis JC, Hantgan RR. Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastruc-tural examination of lysis of a model platelet-fibrin thrombus. Blood 1993; 81: 1290–1299.
   PubMed Web of Science ®Google Scholar
• Higazi AA, Mazar A, Wang J et al. Single-chain urokinase-type plasminogen activator bound to its receptor is relatively resistant to plasminogen activator inhibitor type 1. Blood 1996; 87: 3545–3549.
   PubMed Web of Science ®Google Scholar
• Senno SL, Pechet L. Clinical implications of elevated PAT-1 revisited: multiple arterial thrombosis in a patient with essential thrombocythemia and elevated plasminogen activator inhibitor-1 (PAT-1) levels: a case report and review of the literature. J Thromb Thrombolysis 1999; 8: 105–112.
   PubMed Web of Science ®Google Scholar
• Cancelas JA, Garcia-Avello A, Garcia-Frade U. High plasma levels of plasminogen activator inhibitor 1 (PAT-I) in polycythemia vera and essential thrombocythemia are associated with thrombo-sis. Thromb Res 1994; 75: 513–520.
   PubMed Web of Science ®Google Scholar
• Kaftan O, Balcik OS, Cipil H et al. Plasma levels of thrombin-activatable fibrinolysis inhibitor in primary and secondary thrombocytosis. Clin Appl Thromb Hemost 2005; 11: 449–454.
   PubMed Web of Science ®Google Scholar
• Fields W, Freeman NJ. The hypercoagulability of polycythemia vera. Hosp Pract 1993; 28: 65-68, 72–73.
   Google Scholar
• Kaplan ME, Mack K, Goldberg JD, Donovan PB, Berk PD, Wasserman LR. Long-term management of polycythemia vera with hydroxyurea: a progress report. Semin Hematol 1986; 23: 167–171.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Barbui T, Smith CW. Pathogenesis of thrombosis in essential thrombocythemia and polycythemia vera: the role of neutrophils. Semin Hematol 2005; 42: 239–247.
   PubMed Web of Science ®Google Scholar
• Spivak JL. Polycythemia vera: myths, mechanisms, and manage-ment. Blood 2002; 100: 4272–4290.
   PubMed Web of Science ®Google Scholar
• Barbui T, Finazzi G. Risk factors and prevention of vascular complications in polycythemia vera. Semin Thromb Hemost 1997; 23: 455–461.
   PubMed Web of Science ®Google Scholar
• McMullin MF, Bareford D, Campbell P et al. Guidelines for the diagnosis, investigation and management of polycythaemia/ery-throcytosis. Br J Haematol 2005; 130: 174–195.
   PubMed Web of Science ®Google Scholar
• Yarbro JW. Mechanism of action of hydroxyurea. Semin Oncol 1992; 19: 1–10.
   PubMed Web of Science ®Google Scholar
• Pardanani AD, Levine RL, Lasho T et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients. Blood 2006; 108: 3472–3476.
   PubMed Web of Science ®Google Scholar
• Maugeri N, Giordano G, Petrilli MP et al. Inhibition of tissue factor expression by hydroxyurea in polymorphonuclear leuko-cytes from patients with myeloproliferative disorders: a new effect for an old drug? J Thromb Haemost 2006; 4: 2593–2598.
   PubMed Web of Science ®Google Scholar
• Girodon F, Schaeffer C, Cleyrat C et al. Frequent reduction or absence of detection of the JAK2-mutated clone in JAK2V617F-positive patients within the first years of hydroxyurea therapy. Haematologica 2008; 93: 1723–1727.
   PubMed Web of Science ®Google Scholar
• Spanoudakis E, Bazdiara I, Kotsianidis I et al. Hydroxyurea (HU) is effective in reducing JAK2V617F mutated clone size in the peripheral blood of essential thrombocythemia (ET) and poly-cythemia vera (PV) patients. Ann Hematol 2009; 88: 629–632.
   PubMed Web of Science ®Google Scholar